版本:
中国

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

Oct 11 Daiichi Sankyo Co Ltd:

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

* Daiichi Sankyo Co Ltd - looking to combine quizartinib with other investigational agents in Co's pipeline such as MDM2 and BRD4 inhibitors Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐